Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study

Leukemia, Published online: 13 September 2019; doi:10.1038/s41375-019-0545-2Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study

Source: Leukemia - September 12, 2019 Category: Hematology Authors: Yuqin Song Quanli Gao Huilai Zhang Lei Fan Jianfeng Zhou Dehui Zou Wei Li Haiyan Yang Ting Liu Quanshun Wang Fangfang Lv Haiyi Guo Liudi Yang Rebecca Elstrom Jane Huang William Novotny Vivian Wei Jun Zhu Source Type: research